The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Induction Therapy With Autologous Mesenchymal Stem Cells in Living-Related Kidney Transplants: A Randomized Controlled Trial
Abstract
CONTEXT: Antibody-based induction therapy plus calcineurin inhibitors (CNIs) reduce acute rejection rates in kidney recipients; however, opportunistic infections and toxic CNI effects remain challenging. Reportedly, mesenchymal stem cells (MSCs) have successfully treated graft-vs-host disease. OBJECTIVE: To assess autologous MSCs as replacement of antibody induction for patients with end-stage renal disease who undergo ABO-compatible, cross-match-negative kidney transplants from a living-related donor. DESIGN, SETTING, AND PATIENTS: One hundred fifty-nine patients were enrolled in this single-site, prospective, open-label, randomized study from February 2008-May 2009, when recruitment was completed. INTERVENTION: Patients were inoculated with marrow-derived autologous MSC (1-2 x 10(6)/kg) at kidney reperfusion and two weeks later. Fifty-three patients received standard-dose and 52 patients received low-dose CNIs (80% of standard); 51 patients in the control group received anti-IL-2 receptor antibody plus standard-dose CNIs. MAIN OUTCOME MEASURES: The primary measure was 1-year incidence of acute rejection and renal function (estimated glomerular filtration rate [eGFR]); the secondary measure was patient and graft survival and incidence of adverse events. RESULTS: Patient and graft survival at 13 to 30 months was similar in all groups. After 6 months, 4 of 53 patients (7.5%) in the autologous MSC plus standard-dose CNI group (95% CI, 0.4%-14.7%; P = .04) and 4 of 52 patients (7.7%) in the low-dose group (95% CI, 0.5%-14.9%; P = .046) compared with 11 of 51 controls (21.6%; 95% CI, 10.5%-32.6%) had biopsy-confirmed acute rejection. None of the patients in either autologous MSC group had glucorticoid-resistant rejection, whereas 4 patients (7.8%) in the control group did (95% CI, 0.6%-15.1%; overall P = .02). Renal function recovered faster among both MSC groups showing increased eGFR levels during the first month after surgery than the control group. Patients receiving standard-dose CNI had a mean difference of 6.2 mL/min per 1.73 m(2) (95% CI, 0.4-11.9; P=.04) and those in the low-dose CNI of 10.0 mL/min per 1.73 m(2) (95% CI, 3.8-16.2; P=.002). Also, during the 1-year follow-up, combined analysis of MSC-treated groups revealed significantly decreased risk of opportunistic infections than the control group (hazard ratio, 0.42; 95% CI, 0.20-0.85, P=.02) CONCLUSION: Among patients undergoing renal transplant, the use of autologous MSCs compared with anti-IL-2 receptor antibody induction therapy resulted in lower incidence of acute rejection, decreased risk of opportunistic infection, and better estimated renal function at 1 year. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00658073.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
The Banff 97 working classification of renal allograft pathology
Racusen, L. C., Solez, K., Colvin, R. B., Bonsib, S. M., Castro, M. C., Cavallo, T., Croker, B. P., Demetris, A. J., Drachenberg, C. B., Fogo, A. B., et al. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00299.x · Cited by 3,033
Le Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734
Le Blanc, K., Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., Lanino, E., Sundberg, B., Bernardo, M. E., Remberger, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60690-x · Cited by 2,695
Bartholomew, A., Sturgeon, C., Siatskas, M., Ferrer, K., McIntosh, K., Patil, S., Hardy, W., Devine, S., Ucker, D., Deans, R., et al. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(01)00769-x · Cited by 2,295
Ma, Y.-C., Zuo, L., Chen, J.-H., Luo, Q., Yu, X.-Q., Li, Y., Xu, J.-S., Huang, S.-M., Wang, L.-N., Huang, W., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006040368 · Cited by 1,897
Self-citationReduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Ekberg, H., Tedesco-Silva, H., Demirbas, A., Vítko, Š., Nashan, B., Gürkan, A., Margreiter, R., Hugo, C., Grinyó, J. M., Frei, U., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067411 · Cited by 1,810
Immunomodulatory properties of mesenchymal stromal cells
Nauta, A. J., & Fibbe, W. E. (2007) · Blood · doi:10.1182/blood-2007-02-069716 · Cited by 1,788
Deans, R. J., & Moseley, A. B. (2000) · Experimental Hematology · doi:10.1016/s0301-472x(00)00482-3 · Cited by 1,412
Koç, O. N., Gerson, S. L., Cooper, B. W., Dyhouse, S. M., Haynesworth, S. E., Caplan, A. I., & Lazarus, H. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.2.307 · Cited by 1,119
Cited by
Clinical Trials with Mesenchymal Stem Cells: An Update
Squillaro, T., Peluso, G., & Galderisi, U. (2016) · Cell Transplantation · doi:10.3727/096368915x689622 · Cited by 1,395
Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases
Shi, Y., Wang, Y., Li, Q., Liu, K., Hou, J., Shao, C., & Wang, Y. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0023-5 · Cited by 1,223
Mesenchymal stem cells and immunomodulation: current status and future prospects
Gao, F., Chiu, S. M., Motan, D. A. L., Zhang, Z., Chen, L., Ji, H.-L., Tse, H.-F., Fu, Q.-L., & Lian, Q. (2016) · Cell Death & Disease · doi:10.1038/cddis.2015.327 · Cited by 1,121
Eggenhofer, E., Benseler, V., Kroemer, A., Popp, F. C., Geissler, E. K., Schlitt, H. J., Baan, C. C., Dahlke, M. H., & Hoogduijn, M. J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00297 · Cited by 804
Mesenchymal stromal cells: new directions
Keating, A. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.015 · Cited by 778
Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation
Galleu, A., Riffo-Vasquez, Y., Trento, C., Lomas, C., Dolcetti, L., Cheung, T. S., von Bonin, M., Barbieri, L., Halai, K., Ward, S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7828 · Cited by 646
Biological functions of mesenchymal stem cells and clinical implications
Naji, A., Eitoku, M., Favier, B., Deschaseaux, F., Rouas-Freiss, N., & Suganuma, N. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03125-1 · Cited by 624
de Witte, S. F. H., Luk, F., Sierra Parraga, J. M., Gargesha, M., Merino, A., Korevaar, S. S., Shankar, A. S., O'Flynn, L., Elliman, S. J., Roy, D., et al. (2018) · Stem Cells · doi:10.1002/stem.2779 · Cited by 504
Kabat, M., Bobkov, I., Kumar, S., & Grumet, M. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0202 · Cited by 444
Regulatory immune cells in transplantation
Wood, K. J., Bushell, A., & Hester, J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3227 · Cited by 431
Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices
Sharma, R. R., Pollock, K., Hubel, A., & McKenna, D. (2014) · Transfusion · doi:10.1111/trf.12421 · Cited by 430
Mesenchymal Stem Cells Deliver Exogenous MicroRNA-let7c via Exosomes to Attenuate Renal Fibrosis
Wang, B., Yao, K., Huuskes, B. M., Shen, H.-H., Zhuang, J., Godson, C., Brennan, E. P., Wilkinson-Berka, J. L., Wise, A. F., & Ricardo, S. D. (2016) · Molecular Therapy · doi:10.1038/mt.2016.90 · Cited by 379
Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells
Leibacher, J., & Henschler, R. (2016) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0271-2 · Cited by 367
Reinders, M. E. J., de Fijter, J. W., Roelofs, H., Bajema, I. M., de Vries, D. K., Schaapherder, A. F., Claas, F. H. J., van Miert, P. P. M. C., Roelen, D. L., van Kooten, C., et al. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0114 · Cited by 339
Kidney Transplantation in Children
Dharnidharka, V. R., Fiorina, P., & Harmon, W. E. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1314376 · Cited by 265
Mesenchymal stem cell-educated macrophages
Eggenhofer, E., & Hoogduijn, M. J. (2012) · Transplantation Research · doi:10.1186/2047-1440-1-12 · Cited by 169
Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target
Chen, J., Liu, Q., He, J., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.958790 · Cited by 164
Self-citationMicroencapsulated human mesenchymal stem cells decrease liver fibrosis in mice
Meier, R. P. H., Mahou, R., Morel, P., Meyer, J., Montanari, E., Muller, Y. D., Christofilopoulos, P., Wandrey, C., Gonelle-Gispert, C., & Bühler, L. H. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.030 · Cited by 153
Detry, O., Vandermeulen, M., Delbouille, M.-H., Somja, J., Bletard, N., Briquet, A., Lechanteur, C., Giet, O., Baudoux, E., Hannon, M., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.001 · Cited by 129
BULUT, Ö., & GÜRSEL, İ. (2020) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-2002-79 · Cited by 34
Amadeo, F., Trivino Cepeda, K., Littlewood, J., Wilm, B., Taylor, A., & Murray, P. (2021) · Emerging Topics in Life Sciences · doi:10.1042/etls20210013 · Cited by 20
He, T., Zhou, B., Sun, G., Yan, Q., Lin, S., Ma, G., Yao, Q., Wu, X., Zhong, Y., Gan, D., et al. (2024) · Cell Death & Differentiation · doi:10.1038/s41418-023-01243-9 · Cited by 19
Metadata
- Authors
- Tan, J., Wu, W., Xu, X., Liao, L., Zheng, F., Messinger, S., Sun, X., Chen, J., Yang, S., Cai, J., Gao, X., Pileggi, A., & Ricordi, C.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2012-03-21
- Volume
- 307
- Issue
- 11
- Pages
- 1169
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2060437379
- Cited by
- 553
- References
- 28
- FWCI
- 46.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.